Kornimate/medical-research-clean huggingface dataset:
assessment and monitoring of patients in medium-term heart transplant candidates undergoing low-intensity exercise

Conditions: Heart Failure

Summary: objectives: to study the behavior and cardiovascular safety protocol to the front low-intensity exercise in patients with heart failure (hf) severe, awaiting heart transplantation. methods: the investigators studied 21 patients with severe hf on the list for a heart transplant at the university hospital of unifesp. after evaluation, patients underwent exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents. these also were followed for an average period of 17 months as the clinical complications and death. results: from the patients studied, three were not able to perform the full protocol, and the variables body mass index, maximal inspiratory and expiratory pressure measurement (pimáx and pemáx, cmh2o) and number of previous admissions, showed the most divergent behavior of the sample studied. a greater increase in heart rate, double product and scale of perceived exertion during step 5 was observed during the protocol. blood pressure levels showed little change between stages, and there was no arrhythmias incidence increase (kappa = 0.552) compared to effort. a positive correlation scale was perceived in exertion walking distance of 200m, with systolic blood pressure (r = 0.4, p = 0.02). overall observed lower values of maximal inspiratory pressure and increased blood pressure and elevated heart rate in patients with death outcome. conclusion: cardiovascular behavior against exercise protocol was well tolerated and safe, but suggests need for monitoring. information collected at initial clinical evaluation associated with decompensation and death, and may help stratify these patients.


Eligibility criteria:
inclusion criteria: * heart failure severe, awaiting heart transplantation exclusion criteria: * decompensated heart failure * vasoactive drugs * unstable angina * severe stenosis or insufficiency valvular * recent surgery * morbid obesity

Keywords: exercise heart failure rehabilitation
algorithm-guided transfusions in cardiac surgery patients for reduction of drainage blood losses

Conditions: Chest Tube Output; Allogeneic Blood Transfusions

Summary: cardiac surgery patients have a risk to need allogeneic blood transfusions that depends on several risk factors, e.g. the type of surgery, concomitant medication with anticoagulants, and postoperative chest tube output. allogeneic blood transfusion is associated with transfusion reactions, infection transmission, and postoperative morbidity and mortality. the aim of this study is to investigate, whether cardiac surgery patients have a reduced postoperative chest tube output and transfusion need when using a point-of-care guided transfusion algorithm compared to standard of care transfusion protocols.

cardiac surgery patients have a risk to need allogeneic blood transfusions that depends on several risk factors, e.g. the type of surgery, concomitant medication with anticoagulants, and postoperative chest tube output. allogeneic blood transfusion is associated with transfusion reactions, infection transmission, and postoperative morbidity and mortality. the aim of this study is to investigate, whether cardiac surgery patients have a reduced postoperative chest tube output and transfusion need when using a point-of-care guided transfusion algorithm compared to standard of care transfusion protocols .

Eligibility criteria:
inclusion criteria: * elective cardiac surgery patient requiring cardiopulmonary bypass * moderate or high transfusion risk * signed informed consent exclusion criteria: * age \ 80 years * known hemophilia * known thrombophilia * known thrombocytopathy * hereditary or acquired coagulation disorder * active endocarditis * ejection fraction \<30% * bsa \< 1.8 sqm * planned aortic arch surgery * preoperative thrombocytopenia \<150/nl * underlying hemostaseological disease * preoperative anemia * liver cirrhosis child b or higher * preoperative creatinine \> 2mg/dl * terminal renal insufficiency requiring dialysis * vitamin k antagonists during 5 days prior to surgery * pregnant or breast-feeding women * known allergy against allogeneic blood products or coagulation factors * refusal of blood transfusions * any concomitant investigational agent or participation in another trial

Keywords: poc rotem multiplate transfusion cardiac surgery drainage blood loss chest tube output
mandibular advancement device for obstructive sleep apnea

Conditions: Sleep Apnea Syndromes; Sleep Apnea; Obstructive Sleep Apnea

Summary: the purpose of this study was to determine how effective a custom-made standard dental splint (activator) advancing the lower jaw forward is in treatment of obstructive sleep apnea, and further to find factors for identification of those patients likely to benefit from this treatment.

obstructive sleep apnea (osa) is far the most common sleep disordered breathing, affecting 2-4% of the adult population. the repetitive obstructions are located in the pharyngeal airway, leading to sleep fragmentation and resulting in excessive daytime sleepiness with consequences for ability to work, road safety and quality of life. furthermore, osa is an independant riskfactor for cardiovascular disease. the treatment of choice today is continuous positive airway pressure (cpap) but a main problem with cpap is an unsatisfactory compliance. an alternative conservative more user-friendly treatment could be oral appliances, intending to increase the pharyngeal airway directly by tongue retaining devices or indirectly by mandibular advancing devices. though several randomized studies on oral appliances have come recent years, all giving some evidence for effect on osa, they all had some shortcomings, such as using crossover design, small sample sizes, under-reporting of methods and data and lack of blinding. in this study of a mandibular advancement device was used a parallel group design with an inactive device and no intervention as controls. beside the effect on sleep, daytime sleepiness and quality of life, the study aimed to find objective factors to be used as predictors of the outcome.

Eligibility criteria:
inclusion criteria: * ahi \> 5 on polysomnography * sufficient set of teeth to hold a splint * written informed consent exclusion criteria: * sleep apnea with severe cardiovascular disease * other severe somatic or psychiatric disease * periodontal disease * significant occlusal dysfunction * pregnant women

Keywords: oral appliances obstructive sleep apnea epworth sleepiness scale sf-36
small bowel motility in patients with systemic sclerosis

Conditions: System Sclerosis

Summary: several studies using intestinal manometry have reported alterations in small bowel motility in patients with systemic sclerosis. our aim is to apply endoluminal image analysis to stratify the intestinal motor dysfunction in these patients can be assessed by non-invasive techniques. consecutive patients with systemic sclerosis referred to our institution will be prospectively investigated using automated non-invasive techniques developed in our laboratory. intraluminal images of the gut were obtained by capsule endoscopy. endoluminal image analysis will be performed with original, previously validated programs based on computer vision and machine learning techniques.


Eligibility criteria:
inclusion criteria: * systemic sclerosis diagnosed by acr criteria exclusion criteria: * lung transplantation * end stage kidney disease
efficacy of acute intake of ketones on performance in professional road cyclists

Conditions: Ketoses, Metabolic; Ketosis

Summary: randomized, controlled, double-blind, crossover clinical trial, depending on the product consumed, to analyze the efficacy on physical performance of a sports supplement consumed prior to and during competition or training.

subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product or placebo, depending on the group to which they have been assigned). on the second day, participants will consume the product that subjects did not consume on the first day. the product to be consumed will be ketone monoester. participants will consume 800 mg/kg body weight, distributed in two intakes. the first one, half an hour before exercise and the same dose will be consumed one hour and a half after the first dose. the intakes will be accompanied by carbohydrates and bicarbonate. the tests that the cyclists will perform are a time trial on a cycloergometer to measure performance, as well as a 30" sprint. afterwards, the cyclists will do a 4 and a half hour training session at competition pace. after this training session, the participants will do the same time trial and the 30'' sprint.

Eligibility criteria:
inclusion criteria: * male professional cyclists. * start the study with previous rest. exclusion criteria: * participant suffering from chronic illness. * suffering a long-term injury that prevents her from training in the month prior to the intervention. * inability to understand the informed consent. * having consumed ketone bodies chronically in the previous four weeks. * to have undergone cholecystectomy.
to compare intravenous and oral hydration of the prevention for cin in elderly patients undergoing intravenous cect

Conditions: CIN

Summary: to compare intravenous and oral hydration of the prevention for contrast-induced nephropathy in elderly patients undergoing intravenous contrast-enhanced computed tomography.

the prospective multicenter randomized controlled clinical research discusses the comparison of oral and intravenous hydration for prevention of contrast-induced nephropathy in elderly patients with enhanced computed tomography, establishing a simple hydration proposal.

Eligibility criteria:
inclusion criteria: * age\>21 * informed consent * undergoing intravenous contrast-enhanced computed tomography exclusion criteria: * ct enhancement was not performed; * dialysis treatment of patients with end-stage renal failure or heart, kidney transplantation; * exposure to radioactive contrast medium within 48 hours prior to or within 72 hours of examination; * acute decompensated heart failure; * allergic to radioactive contrast agent; * be subjected to life - threatening trauma; * severe infection; * surgery was performed within 2 days of ct examination. * combined with multiple myeloma, urinary obstruction, aortic dissection * can cause acute kidney injury disease; * use of aminoglycosides and other nephrotoxic drugs 2 weeks before.

Keywords: cin hydration enhanced computed tomography
effects of abrocitinib treatment on skin barrier function

Conditions: Atopic Dermatitis

Summary: effects of abrocitinib treatment of atopic dermatitis on skin barrier function.

open-label, non-randomized, single-arm, 12-weeks observational clinical and translational study

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained from the subject prior to performing any protocol-related pro-cedures, including screening evaluations 2. age ≥ 18 years at time of study entry. 3. diagnosis of chronic atopic dermatitis for at least 1 year prior to enrollment based on american academy criteria 4. eczema area and severity index (easi) score ≥12 at baseline visit (week 0) 5. investigator global assessment (iga) ≥3 at baseline visit (week 0) 6. subject is willing and able to comply with the protocol for the duration of the study 7. subject receives abrocitinib by the treating dermatologist within routine care exclusion criteria: 1. 1. subject is unable to provide written informed consent or comply with the protocol 2. concurrent enrolment in another clinical trial where the subject is receiving an imp or participation in another clinical trial with investigational product during the last 30 days before inclusion or 7 half-lives of previously used trial medication, whichever is longer. 3. active dermatologic conditions that may confound the diagnosis of ad or would interfere with as-sessment of treatment, such as scabies, cutaneous lymphoma, or psoriasis. 4. known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of ad. 5. having used systemic immunosuppressive/immunomodulating therapy (e.g. systemic corticoster-oids methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, jak inhibitors) or tanning beds or phototherapy during any week within the 4 weeks or receipt of any marketed biologic ther-apy (e.g., dupilumab, tralokinumab) within 3 months or 5 half-lives, whichever is longer, prior to baseline 6. treatment of selected marker skin areas (non-lesional skin at volar forearm and extensor forearm, lesional skin) with topical corticosteroid or topical calcineurin inhibitor 1 week prior to baseline visit and throughout the study. 7. treatment of skin areas of examination with emollients 24 hours prior to baseline visit and throughout the study. 8. involvement in the planning and/or conduct of the study.

Keywords: skin barrier atopic dermatitis dermatology skin physiology
bioflow-india safety and clinical performance of the drug eluting orsiro stent in single de novo coronary artery lesions

Conditions: Coronary Artery Disease

Summary: the objective of this clinical investigation is to assess the safety and clinical performance of the orsiro limus eluting stent system in indian subjects with single de-novo coronary artery lesions.


Eligibility criteria:
main inclusion criteria: * subject has provided a written informed consent * single de novo lesion with ≥ 50% and \<100% stenosis in up to 2 coronary arteries * the target lesion length is ≤ 26 mm * the target reference vessel diameter is ≥ 2.0 mm and ≤ 4.0 mm main exclusion criteria: * evidence of myocardial infarction within 72 hours prior to index procedure * unprotected left main coronary artery disease (stenosis \>50%) * three-vessel coronary artery disease at time of procedure thrombus in target vessel * target lesion involves a side branch \> 2.0 mm in diameter * heavily calcified lesion * target lesion is located in or supplied by an arterial or venous bypass graft
impact of sinus surgery on individuals with cystic fibrosis

Conditions: Chronic Rhinosinusitis (Diagnosis); Cystic Fibrosis

Summary: this study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (crs). individuals who do not undergo surgery but are treated medically for crs will also be enrolled to serve as a control group. outcomes analyzed will include pulmonary, quality of life, and others.


Eligibility criteria:
inclusion criteria: 1. subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive, subjects over the age of 89 will be recorded to be 89 years old). 2. diagnosed with cystic fibrosis as established by genetic testing combined with clinical assessment and/or sweat chloride 3. diagnosed with chronic rhinosinusitis by multidisciplinary sinusitis guidelines 4. chronic rhinosinusitis symptoms persisting beyond initial medical treatment 5. counseled for endoscopic sinus surgery and ongoing medical therapy with each patient electing their preferred treatment exclusion criteria: 1. underwent endoscopic sinus surgery in past 12 months 2. will obtain follow up care at non-participating institutions 3. unable to complete follow-up surveys

Keywords: chronic rhinosinusitis cystic fibrosis endoscopic sinus surgery
examination of factors associated with fatigue in individuals diagnosed with parkinson's disease

Conditions: Parkinson Disease; Fatigue

Summary: fatigue is defined as an overwhelming feeling of weariness, lack of energy, and a feeling of exhaustion. it is common in parkinson's disease (pd) and is one of the most disabling symptoms. fatigue is affected by motor and non-motor symptoms in individuals diagnosed with pd. as a result of this impact, it manifests itself as difficulty in initiating and continuing mental and physical tasks. this study aims to examine the fatigue of individuals diagnosed with pd and the factors associated with this fatigue.

the study will be carried out in cooperation with gazi university faculty of health sciences, department of physiotherapy and rehabilitation and nigde omer halisdemir university, and the study data will be collected from individuals diagnosed with pd who applied to the neurology polyclinic of nigde omer halisdemir university training and research hospital. necessary permissions have been obtained from all institutions. modified hoehn\&yahr staging (hys) and unified parkinson's disease rating scale (updrs and its subtests) will be used for disease staging and grading. parkinson's fatigue scale-16 (pfs-16) to evaluate fatigue, parkinson's disease sleep scale-2 (pdss-2) to evaluate sleep, hospital anxiety and depression scale (had) to evaluate depression and anxiety, mini-mental to evaluate cognitive status (mmse) will be used. in addition, "timed up and go (tug)" will be applied for lower extremity performance evaluation. all evaluations will be collected in a single meeting using the face-to-face interview method. it is calculated that 80% power will be reached with a margin of error of 0.05 when 84 individuals diagnosed with pd are included in the study.

Eligibility criteria:
inclusion criteria: * being 18 years or older, * being diagnosed with pd by a neurologist, * having stable medical treatment, * being able to stand independently for at least 60 seconds without any assistive device, * having received 18 points or more according to the mmsd evaluation. exclusion criteria: * being illiterate or unable to communicate in turkish, * having undergone a surgery that may affect lower extremity functions, * diabetes mellitus is a diagnosis of another neurological and rheumatic disease.

Keywords: parkinson's disease fatigue examination
influence of osteoporosis on clinical outcomes of mini-invasive surgical treatment of proximal humerus fractures

Conditions: Osteoporosis; Humerus Fracture

Summary: aim of the study is to analyze results of treatment of proximal humerus fractures with mini-invasive technique and plate fixation. in all the patients a analysis of presence of osteoporosis will be done, clinical and x-ray results will be statistically analyzed to evidence any connection between clinical outcomes and osteoporosis.


Eligibility criteria:
inclusion criteria: * proximal humerus fracture exclusion criteria: * high risk to surgery (asa 4 - 5)
sofosbuvir/simeprevir plus a flat dose of ribavirin in genotype 1 elderly hcv cirrhotic patients

Conditions: Liver Cirrhosis

Summary: the proportion of hcv infected patients over age 65 years in western countries is increasing. this growth and the advent of new antiviral therapy bring into the question the real world efficacy and safety of the combination of sofosbuvir and simeprevir (sof/smv) plus a flat dose of ribavirin (rbv) in elderly patients compared to younger patients.

the proportion of hcv infected patients over age 65 years in western countries is increasing. this growth and the advent of new antiviral therapy bring into the question the real world efficacy and safety of the combination of sofosbuvir and simeprevir (sof/smv) plus a flat dose of ribavirin (rbv) in elderly patients (group ii) compared to younger patients (group i) multicenter, real world investigation study of once daily treatment with sof 400 mg + smv 150 mg with a flat dose of rbv 800 mg/day for a duration of 12 weeks in treatment naïve or experienced hcv genotype 1-infected patients with compensated cirrhosis.to evaluate efficacy, tollerability and safety of sof/smv/rbv in two different group of patients.

Eligibility criteria:
inclusion criteria: * naive or experienced patients with genotype 1 compensated cirrhosis exclusion criteria: * hiv and hepatitis b infection, active hepatocellular carcinoma (hcc), decompensated cirrhosis, history of organ transplant, severe psychiatric disorders or treatment with drugs that showed an interaction with antiviral treatment.
a two-day education program for metabolic syndrome patients

Conditions: Metabolic Syndrome

Summary: this study was to evaluate the temporal change of metabolic indicators and quality of life by a two-day patient education program.

this study aimed to evaluate whether a two-day multidisciplinary education camp comprising doctors, nurses, exercise instructors, dietitians, social workers, and health administrators could initiate healthy lifestyle habits, improve health markers though lifestyle modification, increase knowledge and understanding of the disease, and have a profitable effect on mental health in relation to depression and quality of life for patients with metabolic syndrome.

Eligibility criteria:
inclusion criteria: * people satisfied with metabolic syndrome criteria exclusion criteria: * none

Keywords: metabolic syndrome motivation patient education quality of life
internet-based cognitive behavioral therapy for adult attention deficit hyperactivity disorder

Conditions: ADHD

Summary: attention deficit hyperactivity disorder (adhd) is a disorder characterized by lack of attention, hyperactivity, and impulsivity. it can have major impact on everyday life and result in negative consequences for one's personal, academic, and work situation. for individuals with symptoms of adhd, increased levels of anxiety and depression are common, and an overall reduction of quality of life is often present. this study protocol describes a clinical trial of internet-based cognitive behavioral therapy (icbt), using a randomized controlled study design, with the primary aim to increase quality of life, as well as to reduce symptoms of adhd, anxiety, depression, and stress. a second aim is to investigate, by qualitative means, what aspects of treatment were perceived as helpful and hindering when it comes to completing icbt. two hundred participants with symptoms of adhd will be included and randomized to two conditions (treatment and wait-list control). the treatment period is comprised of ten weeks, with two mandatory modules and ten modules from which the participants can choose freely. self-report measures are completed by the participants at baseline and end of treatment, as well as at a six-month follow-up. the treatment is guided by therapists and consists of weekly correspondence with the participants. the study will utilize an intention to treat design, with anovas and reliable change index to evaluate treatment effects. the qualitative part of the project will be interview-based and employ thematic analysis. lastly, a psychometric evaluation of a common instrument for determining adhd-symptoms will also be made. the results will hopefully contribute to the evidence base for icbt for individuals with symptoms of adhd and help disseminate potentially effective interventions.


Eligibility criteria:
inclusion criteria: 1. over 18 years old of age. 2. can read and write in swedish. 3. have access to a computer, tablet, or smartphone with an internet connection. 4. have previously been diagnosed with adhd. 5. are studying at a university or college in sweden or working at least 50% of a full time-employment. exclusion criteria: 1. shows elevated symptoms of depression or risk of suicide, i.e., a total score on the patient health questionnaire - 9 items (phq-9; kroenke, k., spitzer, r. l., \& williams, j. b. (2001)), \> 15 points, or scores \> 2 points on question i) concerning suicidality. 2. has started or changed their medication for any psychiatric diagnosis in the last three months. 3. exhibits another form of psychiatric diagnosis that requires more specialized care, for example substance abuse syndrome, anorexia nervosa, bipolar disorder, psychotic symptoms, or schizophrenia, as assessed with the mini (sheehan et al., 1998).